刘泽众

药理学,青年研究员,博士生导师

发布时间:2022-09-13浏览次数:5362

姓      名

 刘泽众

性      别

 男

职      称

 青年研究员

学      历

 博士

电      话

 

传      真

 

电子邮件

 zzliu17@fudan.edu.cn

个人主页

 

通讯地址

 上海市浦东新区张衡路826号复旦大学药学院科研楼211

 

教育经历

2017.09 – 2020.08 复旦大学,病原生物学,博士

2014.09 – 2017.07 中国农业科学院,预防兽医学,硕士

2009.09 – 2014.07 西北农林科技大学,动物医学,本科


工作经历

2022.09- 现在 复旦大学药学院 青年研究员

2020.09 – 2022.08 复旦大学 基础医学院 博士后


承担科研项目情况

国家自然科学基金委员会,青年项目,基于串联RBD蛋白和新型STING激动剂佐剂的β属冠状病毒亚单位广谱疫苗及其机制的研究 (2023-2025,20万,主持)

复旦大学引进人才科研基金(2021-2024,300万,主持)

中国博士后科学基金面上项目(2021-2022,8万,主持)

国家自然科学基金委员会,专项项目,激发广谱、持久、强效保护性免疫反应的新型STING激动剂佐剂及其机制的研究 (2021-2022,100万,参与)

国家自然科学基金委员会,专项项目,基于RBD的广谱抗β属冠状病毒B亚群(β-CoVB)新型疫苗的设计及其机制研究 (2020-2022,150万,参与)


获奖及荣誉

复旦大学优秀博士后  2022


研究方向

1.新发突发传染病防治策略研究

2.新型佐剂的研究

3.高效广谱抗病毒疫苗的研究(冠状病毒/流感病毒/肠道病毒)

4.抗病毒多肽以及抗体类药物的研究


科研成果

本团队研究工作集中在研发高效广谱的抗病毒疫苗和药物方向,代表性成果包括:

1.发现了一种可瞬时、强效并安全激活先天免疫的原创新型STING小分子激动剂,将该STING激动剂作为原始新冠病毒蛋白疫苗的佐剂,可对目前已有的新冠病毒全部的变异株包括奥密克戎,甚至是SARS相关冠状病毒都能产生广谱、持久、强效的免疫保护作用,实现了“以不变应万变”的疫苗免疫策略,解决了目前大部分新冠疫苗需要根据新冠病毒变异株的出现不断更新抗原的难题。同时,该新型STING激动剂佐剂也可以作为一种通用佐剂。目前该疫苗已经获得技术转化。

2.首次研发出了First-in-class广谱抗肠道病毒多肽类抑制剂,有望进一步开发为治疗手足口病等肠道病毒感染的新型药物,同时也可为其它重要病毒的抗病毒药物研发提供新思路和策略,研究被Faulty Opinion推荐。

3.发现了一系列广谱新冠病毒中和抗体,并鉴定了中和表位,揭示了抗体体外ADE和促进膜融合的作用机制,为设计广谱新冠病毒疫苗提供了新思路。


专利

1.陆路;姜世勃;刘泽众;周洁;徐巍;一种融合蛋白、核酸分子、载体、宿主细胞及应用,2021.12.28, 中国,202111625737.9

2.LU Lu, JIANG Shibo, LIU Zezhong,HSIEH Ming,ZHANG Yilong,ZHOU Jie,WANG Qian,WANG Xinling, XU Wei. Compounds and their use as vaccine adjuvants, 2021.05.24, PCT, PCT/CN2021/095498

3.王乔;陆路;周韵娇;刘泽众;针对SARS-CoV-2的无ADE效应的中和抗体,2020.09.14,中国,202010960985.8

4.杨霞;陆路;姜世勃;花晨;刘泽众;多肽、其生产方法和用途,2020.03.06,中国,ZL201910111553.7(已授权)

5.陆路;姜世勃;刘泽众;叶绿素铜钠盐在制备用于抗肠道病毒的药物中的应用,2020.03.02,中国,202010135530.2

6.杨霞;姜世勃;陆路;刘泽众;一种广谱抗肠道病毒的蛋白类药物及其应用, 2019.12.24,中国,201911343541.3

7.ZHOU Xi,LU Lu,FANG Yuan,JIANG Shibo,LIU Zezhong,QIN Chengfeng,QIU Yang,MU Jingfang. Broad-Spectrum Polypeptide against Enterovirus and Application Thereof。2018.01.20, PCT, PCT/CN2019/072455

8.常惠芸;刘泽众;邵军军;赵付荣;李秀梅;张永光;一种猪口蹄疫3ABC和2C抗体化学发光检测试剂盒, 2016.11.25, 中国,ZL201611051539.5(已授权)

9.常惠芸;刘泽众;邵军军;赵付荣;李秀梅;张永光;一种牛口蹄疫3ABC抗体化学发光检测试剂盒,2016.11.25,中国,ZL201611052512.8 (已授权)


代表性论著

1Z. Liu, L. Lu, S. Jiang*. Up or down: where comes Omicron?. Cell Research 32(7):601-602 (2022). (IF:46.297)

2. N. Zhang#, Q. Ji#, Z. Liu#, K. Tang, Y. Xie, K. Li, J. Zhou, S. Li, H. Shang, Z. Shi, T. Zheng, J. Yao, L. Lu*, S. Yuan*, S. Jiang*. Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant. Viruses 14(3):501 (2022).(IF:5.815)

3. Z. Liu#, JF. Chan#, J. Zhou#, M. Wang#, Q. Wang, G. Zhang, W. Xu, KK. Chik, Y. Zhang, Y. Wang*, KY. Yuen*, L. Lu*, S. Jiang*. A Pan-sarbecovirus Vaccine Induces Highly Potent and Durable Neutralizing Antibody Responses in Non-human Primates against SARS-CoV-2 Omicron Variant. Cell Research 32(5):495-497 (2022). (IF:46.297)

4. Z. Liu#, J.Zhou#, W. Xu#, W. Deng#, Y. Wang#, M. Wang#, Q. Wang, M. Hsieh, J. Dong, X. Wang, W. Huang, L. Xing, M. He, C. Tao, Y. Xie, Y. Zhang*, Y. Wang*, J. Zhao*, Z. Yuan*, C. Qin*, S. Jiang*, L. Lu*. A novel STING Agonist-Adjuvanted Pan-Sarbecovirus Vaccine Elicits Potent and Durable Neutralizing Antibody and T Cell Responses in Mice, Rabbits and NHPs.Cell Research. 32(3):269-287 (2022). (IF:46.297)

5. Z. Liu#, W. Xu#, Z. Chen#, W. Fu#, W. Zhan#, Y. Gao#, J. Zhou#, Y. Zhou, J. Wu, Q. Wang, X. Zhang, A. Hao, W. Wu, Q. Zhang, Y. Li, K. Fan, R. Chen, Q. Jiang, CT. Mayer, T. Schoofs, Y. Xie, S. Jiang, Y. Wen, Z. Yuan*, K. Wang*, L. Lu*, L. Sun*, Q. Wang*. An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Protein Cell. 13(9):655-675 (2022). (IF:15.328)

6. J. Zhou#, W. Xu#, Z. Liu#, C. Wang#, S. Xia, Q. Lan, Y. Cai, S. Su, J. Pu, L. Xing, Y. Xie*, L. Lu*, S. Jiang*, Q. Wang*. A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharmaceutica SinicaB. 12(4):1652-1661 (2022). (IF:14.903)

7. Y. Fang#, Z. Liu#, Y. Qiu#, J. Kong, Y. Fu, Y. Liu, C. Wang, J. Quan, Q. Wang, W. Xu, L. Yin, J. Cui, Y. Xu, S. Curry, S. Jiang, L. Lu*, X. Zhou*. Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo. Immunity. 54(10):2231-2244.e6 (2021). (IF:43.373) (封面,被Faulty Opionon推荐)

8. Y. Zhou#, Z. Liu#*, S. Li#, W. Xu#, Q. Zhang, IT. Silva, C. Li, Y. Wu, Q. Jiang, Z. Liu, Q. Wang, Y .Guo, J. Wu, C. Gu, X. Cai, D. Qu, CT. Mayer, X. Wang, S. Jiang, T. Ying, Z. Yuan*, Y. Xie*, Y. Wen*, L. Lu*, Q. Wang*.Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Reports. 34(5):108699 (2021). (IF:9.995)

9. Z. Liu#, W. Xu#, S. Xia#, C. Gu#, X. Wang, Q. Wang, J. Zhou, Y. Wu, X. Cai, D. Qu, T. Ying, Y. Xie, L. Lu*, Z. Yuan*, S. Jiang*. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy. 5(1):282 (2020). (IF:38.104)

10. Z. Liu#, S. Xia#, X. Wang, Q. Lan, W. Xu, Q. Wang, S. Jiang*, L. Lu*. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virol Sin. 35(3):340-343 (2020). (IF:6.947)

11. Z. Liu, S. Xia, X. Wang, Q. Lan, P. Li, W. Xu, Q. Wang, L. Lu*, S. Jiang*. Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. ACS Infect Dis. 26(5):882-890 (2020).(IF:5.578)

12. Z. Liu, J. Shao, F. Zhao, G. Zhou, S. Gao, W. Liu, J. Lv, X. Li, Y. Li, H. Chang*, Y. Zhang*. Chemiluminescence Immunoassay for the Detection of Antibodies against the 2C and 3ABC Nonstructural Proteins Induced by Infecting Pigs with Foot-and-Mouth Disease Virus. Clin Vaccine Immunol. 24(8):e00153-17 (2017). (IF:2.872)

13. Z. Liu*, F. Zhao, S. Gao, J. Shao, H. Chang*. The Applications of Gold Nanoparticle-Initialed Chemiluminescence in Biomedical Detection. Nanoscale Res Lett. 11(1):460 (2016). (IF:4.703)

联系我们
地址:上海浦东新区张衡路826号
电话:(021-51980000)
邮编:201203